HC Wainwright Reaffirms Buy Rating for Oculis (NASDAQ:OCS)

Oculis (NASDAQ:OCS)‘s stock had its “buy” rating reaffirmed by stock analysts at HC Wainwright in a research report issued to clients and investors on Wednesday, Benzinga reports. They currently have a $30.00 price target on the stock. HC Wainwright’s price objective would suggest a potential upside of 89.75% from the stock’s previous close.

Oculis Price Performance

Oculis stock opened at $15.81 on Wednesday. The stock has a market capitalization of $640.37 million, a price-to-earnings ratio of -8.88 and a beta of 0.30. Oculis has a 52-week low of $9.05 and a 52-week high of $16.70. The stock’s 50 day moving average price is $12.73 and its two-hundred day moving average price is $12.15. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.27 and a current ratio of 5.27.

Oculis (NASDAQ:OCS) last issued its earnings results on Tuesday, August 27th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.13). The firm had revenue of $0.27 million during the quarter, compared to the consensus estimate of $0.28 million. Oculis had a negative return on equity of 61.33% and a negative net margin of 7,679.05%. On average, equities analysts predict that Oculis will post -2.19 earnings per share for the current year.

Oculis Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.